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Introduction: Carotid artery dissection (CAD) and atherosclerotic carotid artery
occlusion (ACAO) are major causes of a tandem occlusion in patients with intracranial
large vessel occlusion (LVO). Presence of tandem occlusions may hamper intracranial
access and potentially increases the risk of procedural complications of endovascular
treatment (EVT). Our aim was to assess neurological, functional and technical outcome
and complications of EVT for intracranial LVO in patients with CAD in comparison to
patients with ACAO and to patients without CAD or ACAO.
Methods: We analyzed data of the MR CLEAN trial intervention arm and MR CLEAN
Registry, acquired in 16 Dutch EVT-centers. Primary outcome was the change in stroke
severity by comparing the National Institute of Health Stroke Scale (NIHSS) score
at 24–48 h after treatment vs. baseline. Secondary outcomes included reperfusion
rate and symptomatic intracranial hemorrhage (sICH). We compared outcomes and
complications between patients with CAD vs. patients with ACAO and patients without
CAD or ACAO.
Results: In total, we identified 74 (4.7%) patients with CAD, 92 (5.9%) patients with
ACAO and 1398 (89.4%) patients without CAD or ACAO. Neurological improvement
at short-term after EVT in patients with CAD was significantly better compared to
ACAO (resp. mean −5 vs. mean −1 NIHSS point; p = 0.03) and did not differ
compared to patients without CAD or ACAO (−4 NIHSS points; p = 0.62). Rates of
successful reperfusion in patients with CAD (47%) was comparable to patients with
ACAO (47%; p = 1.00), but was less often achieved compared to patients without
CAD or ACAO (58%; p = 0.08). Occurrence of sICH did not differ significantly between
CAD patients (5%) and ACAO (11%; p = 0.33) or without CAD/ACAO (6%; p = 1.00).
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Conclusion: EVT in patients with intracranial LVO due to CAD results in neurological
improvement comparable to patients without tandem occlusions. Therefore, carotid
artery dissection by itself should not be a contraindication for endovascular treatment
in stroke patients with intracranial large vessel occlusion. Although more challenging
endovascular procedures are to be suspected in both patients with CAD or ACAO,
accurate distinction between CAD and ACAO might influence clinical decision making
as better clinical outcome can be expected in patients with CAD.
Keywords: ischemic stroke, carotid dissection, endovascular treatment, tandem lesion, thrombectomy
INTRODUCTION
In approximately a quarter of all patients with ischemic
stroke due to large vessel occlusion (LVO), ipsilateral extracranial
internal carotid artery (ICA) occlusion is accompanying the
intracranial LVO. This phenomenon is known as tandem
occlusion (1). Major causes of tandem occlusion are carotid
artery dissection (CAD) and atherosclerotic carotid artery
occlusion (ACAO) (2–4). During endovascular treatment (EVT)
of ischemic stroke, the presence of an extracranial tandem
occlusion may constitute a challenge to the neuro-interventionist
as the obstructed internal carotid artery might hamper access to
the intracranial target occlusion and potentially increases the risk
of procedural complications of endovascular treatment (EVT).
Furthermore, an additional reconstruction of a dissected ICA
with a collapse of the true lumen is more challenging than a
straightforward embolic intracranial occlusion.
A meta-analysis of individual patient data of five pivotal
EVT trials showed similar treatment effects in patients with and
without tandem lesions, although no stratification was performed
for the type of tandem lesion (5). However, differences between
CAD and ACAO with regard to clinical outcome after EVT
have been suggested. A post-hoc analysis of the MR CLEAN
trial regarding type of tandem lesion found a strong treatment
effect in patients with CAD and no treatment effect in patients
with ACAO despite the small number of included patients with
CAD (6). On the other hand, in a recent observational study, no
differences in outcomes were observed in EVT-treated patients
with CAD compared to patients with severe atherosclerotic
stenosis or occlusion although patients with CAD were younger
and had less cardiovascular risk factors (7).
The evidence for a benefit of EVT in patients suffering from
concomitant ipsilateral CAD is still scarce (8). On the one hand,
good clinical outcome can be expected in patients with CAD due
to the lower age and the lower prevalence of cardiovascular risk
factors found in this patient group. On the other hand, it could
be suggested that clinical outcome after EVT and interventional
aspects in patients with CAD are comparable to outcomes in
patients with ACAO as successful reperfusion rates may be lower
and procedure times longer than in patients without a tandem
lesion. Furthermore, CAD is known to be a source of emboli
that can lead to re-occlusion or occlusion of a different vascular
territory after initial successful recanalization. This may result in
poorer clinical outcome in patients with successful reperfusion
compared to patients without any extracranial carotid occlusion
(9). The aim of this study was to assess neurological, functional
and technical outcome, as well as safety, after EVT for intracranial
LVO in patients with CAD. Comparisons will be made with
patients with ACAO and patients without CAD or ACAO.
METHODS
Patients
We studied patients who were included in the MR CLEAN trial
or MR CLEAN Registry.
The multicenter randomized MR CLEAN trial consisted of
500 ischemic stroke patients with a NIHSS score of 2 points or
more. After confirmation of a proximal intracranial occlusion of
the anterior circulation on radiographic imaging, patients were
randomized for EVT plus usual care (intervention group) or
usual care only (control group) (10). For the current study, only
patients randomized in the intervention group were included.
Written informed consent before randomization was provided by
all patients or their legal representatives. The study protocol was
approved by a central medical ethics committee and the research
board of each participating center.
The MR CLEAN Registry is an ongoing observational
cohort study of consecutive patients with acute ischemic stroke
undergoing EVT in the Netherlands (11). Enrollment of patients
started directly after the last inclusion in the MR CLEAN trial
on March 16, 2014. EVT consisted of mechanical thrombectomy
and/or aspiration whether or not combined with arterial delivery
of a thrombolytic agent. The exact choice of procedure was left
to the discretion of the interventionist. Included patients in the
current study were treated between March 16, 2014 and June 15,
2016. In order to create a study population comparable to the
MR CLEAN trial, patients from the MR CLEAN Registry were
included in our study when they were 18 years or older and had
undergone EVT for acute ischemic stroke in one of the 16 MR
CLEAN centers. The MR CLEAN Registry was approved by the
ethics committee of the Erasmus University MC, Rotterdam, The
Netherlands and permission to carry out the study as a registry
was granted. With this approval it was approved by the research
board of each participating center. At UMCUtrecht, approval for
the study has been obtained from their own research board and
ethics committee.
In our study, patients with CAD at the symptomatic side
of ischemic stroke were compared to patients with ACAO
to evaluate the relevance of distinguishing different type of
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extracranial carotid occlusions, and to patients without CAD
or ACAO to evaluate the beneficial effects of EVT in patients
with CAD.
Imaging
Assessment of extracranial carotid artery on digital subtraction
angiography (DSA) imaging was performed by an imaging
core lab of neuro-interventionists who were unaware of
clinical characteristics and clinical outcomes. CAD was assessed
on computed tomography angiography (CTA) and digital
subtraction angiography (DSA) and defined as follows: a double
lumen contour with a narrow eccentric true lumen (string sign),
periluminal hematoma and/or widening of the carotid artery
(pseudo-aneurysm). The carotid bulb is spared and the dissection
stops at the skull base. ACAO was defined as an occluded
internal carotid artery with no contrast filling at the level of the
carotid bulb with sign of atherosclerotic disease (calcifications).
The possibility of a pseudo-occlusions caused by hampering of
flow due to distal occlusions was excluded. Pseudo-occlusions
were defined as a gradual decay in contrast filling in the ICA
and a patent carotid bulb. Furthermore, the core lab evaluated
the Alberta Stroke Program Early CT Score (ASPECTS) on
baseline non-contrast CT (NCCT), occluded arterial segment
and collateral grade score on baseline CTA, recanalization grades
by the modified Thrombolysis In Cerebral Infarction (mTICI)
on DSA, and presence of intracranial hemorrhage on follow up
NCCT (12–14).
Outcomes
Primary outcome was the change in stroke severity at short-
term by comparing the National Institute of Health Stroke
Scale (NIHSS) score at 24–48 h after treatment vs. baseline
(delta-NIHSS). A negative delta-NIHSS indicates a neurological
improvement while a positive value indicates a neurological
decline at follow-up. Delta-NIHSS was chosen as primary
outcome for the following reasons (a) lack of a control group
of patients with LVO in whom EVT was not performed; and
(b) baseline differences between the treatment groups which
could result in frailer persons in one group with a subsequent
effect on midterm functional outcomes. Secondary outcomes
were NIHSS at 24 h, functional outcome at 3 months assessed
with the modified Rankin Scale score (mRS), technical success
parameters, and safety parameters.
Technical aspects of interventional procedure were evaluated
regarding duration of procedure (groin puncture to closure
of puncture site), recanalization status (mTICI score), and
occurrence new clots in a different vascular territory. Complete
DSA runs including anteroposterior and lateral views were
required to reach a mTICI score of 2B or higher. Missing lateral
views automatically resulted in a maximum possible mTICI score
of 2A. Successful reperfusion was considered when mTICI 2B or
higher was achieved. In addition, impact of reperfusion grade on
functional outcome was studied.
Safety measures included progression of ischemic stroke
and symptomatic intracranial hemorrhage (sICH). Ischemic
stroke progression was defined as neurological deterioration
of at least 4 points on the NIHSS, in which an intracranial
hemorrhage was excluded as the cause of the deterioration
with CT. ICH was considered symptomatic if the patient
had died or had deteriorated neurologically (a decline of
at least 4 points on the NIHSS), and the hemorrhage was
related to the clinical deterioration (according to Heidelberg
criteria). Both complications were evaluated by the complication
committee consisting of two vascular neurologists and one
neuroradiologist (15).
Statistical Analysis
Baseline characteristics were presented as frequencies, mean with
standard deviation or median and interquartile ranges (IQR).
Intergroup differences were assessed with Fisher’s exact test for
categorical data and Mann-Whitney U test for continuous data.
To evaluate the primary outcome, we assessed the neurological
improvement by subtracting NIHHS at baseline from NIHSS
at follow-up and tested within patient differences with a paired
Wilcoxon signed rank test.
Neurological improvement in patients with CAD compared
to patients with ACAO and to patient without CAD or ACAO
was evaluated with linear regression analysis with NIHSS at
follow up as outcome with adjustments for age, sex, NIHSS
baseline, time from stroke onset to groin puncture, intravenous
thrombolysis (IVT), location of intracranial occlusion, and
collateral status. The functional outcome (mRS score) at long-
term follow-up between the groups were expressed as an
adjusted common odds ratio (acOR) with 95% confidence
interval (95%CI) obtained from ordinal logistic regression with
adjustments for age, sex, NIHSS baseline, time from stroke onset
to groin puncture, intravenous thrombolysis (IVT), location
of intracranial occlusion, and collateral status. For outcome
regression analyses, multiple imputation techniques were used
to provide adjusted, unbiased estimates (16, 17). All analyses
were performed with R statistical software (version 3.4.2)
and additional packages (rms, tableone, haven, Hmisc, ggplot,
and ggpaired).
RESULTS
Of the 233 patients who were allocated to intervention in the
MR CLEAN trial, imaging assessment of the extracranial carotid
artery was insufficient in 11 patients. In total, 222 patients of
the MR CLEAN trial were included in our study. Of the 1,627
patients in the MR CLEAN Registry, 1,342 patients remained,
after exclusion of those younger than 18 years of age, had an
intracranial occlusion in the posterior circulation, were treated
in a non-MR CLEAN trial center, or had insufficient imaging of
the extracranial carotid artery. The combined dataset consisted of
a total of 1,564 patients (Figure 1).
We identified 74 of 1,564 patients (4.7%) with CAD at the
symptomatic side of ischemic stroke of which 15/233 (6.4%)
patients in the MR CLEAN trial and 59/1,342 (4.4%) patients
in the Registry. ACAO at the symptomatic side of stroke was
observed in 92 /1,564 patients (5.9%), leaving 1,398/1,564 (89%)
patients without CAD or ACAO.
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FIGURE 1 | Flowchart of included patients for analysis.
Baseline Patient Characteristics
Compared to patients with ACAO, patients with CAD were
significantly younger and had less cardiovascular risk factors
(Table 1). Furthermore, location of intracranial occlusion did
not differ significantly. In both groups, most intracranial
occlusions were found in the M1 segment of the middle cerebral
artery (Table 1).
Compared to patients without CAD or ACAO, patients with
CAD were more frequently men (resp. 52% vs. 74%; p < 0.001),
were younger (median age 71 years vs. 52 years; p < 0.001)
and cardiovascular risk factors or history regarding diabetes
mellitus, atrial fibrillation, hypertension, myocardial infarction,
and hypercholesterolemia were less frequently present (Table 1).
Median NIHSS scores at baseline were 16 in both groups (median
16 vs. 16 points; p 0.81). In both groups, the M1 segment of
the middle cerebral artery was the most frequent location of the
intracranial occlusion. Patients with CAD more frequently had a
distal ICA or carotid terminus (ICA-T) occlusion, while patients
without ACAO more often had an M2 occlusion (Table 1). On
baseline imaging, patients with CAD had a lower ASPECT scores
(median 8 points vs. 9 points; p 0.23) indicating more ischemic
changes but this difference was not statistically significant.
Duration from stroke onset to groin puncture (median 210min
vs. 235min; p 0.15) and the administration of IVT (78% vs. 85%;
p 0.17) were not statistically different (Table 1).
Primary Outcome
A within-patient comparison showed a significant reduction in
NIHSS in patients with CAD (NIHSS −5±7 points; p < 0.001),
in patient with ACAO (NIHSS −1±9 points; p < 0.001) and
in patients without CAD or ACAO (NIHSS −4±8 points; p <
0.001). In total, we observed a neurological improvement after
EVT (delta-NIHSS<0) in 50/70 (71%) patients with CAD, in
46/81 (57%) patients with ACAO and in 866/1,258 (69%) patients
without CAD or ACAO (Figure 2).
Outcomes in Patients With CAD vs.
Patients With ACAO
Compared to patients who had an extracranial tandem lesion due
to ACAO, patients with CAD had a better neurological outcome
on the NIHSS after adjustments for baseline parameters (NIHSS
points −4.0 [95%CI −7.2–−0.8]) (Table 2). Functional outcome
(mRS) was not significantly better in patients with CAD (acOR
1.72 [95% 0.84–3.50]) (Figure 3). Duration of procedure (resp.
median 80 vs. 74min; p 0.35) and rates of successful reperfusion
(resp. 38/81 (47%) vs. 33/70 (47%); p 1.00) were comparable
between both groups. In addition, we observed similar impact of
reperfusion grade on functional outcome in patients with CAD
and ACAO (Table 4).
Outcomes in Patients With CAD vs.
Patients Without CAD or ACAO
Neurological improvement on the NIHSS at 24–48 h after EVT
in patients with CAD and in patients without CAD or ACAO
was similar (p = 0.62; Table 2). Also, the 24–48 h NIHSS scores
in patients with CAD and patients without CAD or ACAO were
similar after adjustment for baseline parameters (NIHSS points 0
[95%CI−2.1–2.0]).
Patients with CAD had a better functional outcome (mRS at
90 days) than patients without CAD or ACAO (cOR 1.60 [95%CI
1.07–2.38]). However, after adjustment for the prespecified
prognostic factors, this association was no longer significant
(acOR 1.00 [95%CI 0.64–1.56]) (Figure 2).The duration of
procedure was significantly longer in patients with CAD than in
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TABLE 1 | Baseline characteristics of included patients.
Patients with
CAD
(n = 74)
Patients with
ACAO
(n = 92)
Patients without
CAD or ACAO
(n = 1398)
P-value
CAD vs. ACAO
P-value
CAD vs. without CAD
or ACAO
Sex-male (%) 55 (74.3) 72 (78.3) 727 (52.0) 0.69 <0.001
Age-years (median [IQR]) 52 [45–59] 68 [58–77] 71 [60–80] <0.001 <0.001
Smoking (%) 21 (28.4) 36 (39.6) 313 (22.5) 0.18 0.31
Diabetes mellitus (%) 2 (2.7) 15 (16.7) 228 (16.4) 0.01 0.01
Atrial fibrillation (%) 7 (9.6) 3 (3.3) 344 (24.9) 0.17 0.01
Hypertension (%) 18 (24.3) 38 (41.8) 704 (51.0) 0.03 <0.001
Myocardial infarction (%) 2 (2.7) 12 (13.2) 224 (16.3) 0.04 0.01
Previous stroke (%) 6 (8.3) 7 (7.6) 241 (17.3) 1.00 0.07
Hypocholesteremia (%) 5 (6.8) 19 (21.1) 418 (30.8) 0.02 <0.001
Pre-stroke independence (mRS≤2) (%) 70 (95.9) 90 (98.9) 1221 (88.6) 0.46 0.08
Stroke severity at baseline (NIHSS) (median [IQR])a 16 [12–19] 16 [11–19] 16 [12– 20] 0.43 0.81
Location intracranial occlusion (%) 0.42 <0.001
Other 0 (0.0) 0 (0.0) 11 (0.8)
Intracranial ICA 16 (22.2) 17 (18.7) 46 (3.4)
ICA-T 25 (34.7) 33 (36.3) 298 (21.9)
M1 26 (36.1) 39 (42.9) 828 (60.8)
M2 5 (6.9) 2 (2.2) 178 (13.1)
ASPECTS score at baseline (median [IQR])b 8 [7–10] 8 [7–9] 9 [7–10] 0.57 0.23
Collateral grading score (%)c 0.14 0.36
0 2 (2.9) 1 (1.1) 94 (7.0)
1 28 (40.0) 27 (29.7) 435 (32.5)
2 27 (38.6) 32 (35.2) 516 (38.5)
3 13 (18.6) 31 (34.1) 294 (22.0)
Treatment with intravenous thrombolysis (%) 63 (85.1) 79 (85.9) 1086 (77.7) 1.00 0.17
Duration from stroke onset to groin puncture (median [IQR]) 235 [173–295] 211 [178–271] 210 [160–270] 0.54 0.15
aNational Institute of Health Stroke scale (Scores range from 0 to 42, higher scores indicating severe stroke). bAlberta Stroke Program Early Computed tomography Score (Scores
range from 0 to 10 lower scores indicating more early ischemic changes on baseline NCCT). cAssessed at baseline CTA. A score of 0 indicated absent collateral supply to the occluded
territory, 1: filling of >0% but ≤50%, 2: filling of >50% but <100%, 3: filling of 100% collateral supply of the occluded territory.
FIGURE 2 | Paired boxplot of NIHSS points at baseline and follow-up.
patients without CAD or ACAO (median 74 vs. 65min; p 0.01).
Rate of successful reperfusion was significantly lower in patients
with CAD (33/70 (47%) vs. 792/1357 (58%); p 0.08). Among
patients with CAD, progression of ischemic stroke (resp. 12.2%
vs. 11.7%; p 1.00) nor symptomatic intracranial hemorrhage (5%
vs. 6%; p 1.00) occurredmore often than in patients without CAD
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TABLE 2 | Clinical, technical and safety outcomes.
Patients with
CAD
(n = 74)
Patients with
ACAO
(n = 92)
Patients without
CAD or ACAO
(n = 1398)
P-value
CAD vs. ACAO
P-value
CAD vs. without
CAD or ACAO
CLINICAL
Delta-NIHSS (mean [sd]) −5 (7) −1 (9) −4 (8) 0.03 0.62
NIHSS follow up (24−48 h) (median [IQR]) 10 [4–15] 14 [5–20] 11 [4–18] 0.10 0.63
mRS score at 90 days (median [IQR])a 2 [2–4] 4[2–6] 3 [2–6] 0.01 0.01
mRS score at 0−2 at 90 days (%) 36 (51.4) 27 (30.0) 486 (37.3) 0.01 0.02
Mortality within 90 days (%) 8 (11.4) 27 (30.0) 368 (28.2) 0.01 0.01
TECHNICAL
Duration procedure (median [IQR]) 74 [51–99] 80 [57–115] 65 [40–90] 0.35 0.01
New thrombus different vascular territory – no. (%) 4 (22.2) 9 (39.1) 74 (25.6) 0.41 0.97
Successful recanalization (%)b 33 (47.1) 38 (46.9) 792 (58.4) 1.00 0.08
SAFETY
Progression of ischemic stroke (%) 9 (12.2) 15 (16.3) 163 (11.7) 0.60 1.00
Symptomatic intracranial hemorrhage (%)c 4 (5.4) 10 (10.9) 83 (5.9) 0.33 1.00
aModified Rankin scale score was assessed at 90 days after stroke onset. bmTICI ≥ 2B, score of 0 indicates no perfusion or anterograde flow beyond occlusion site, 1: penetration
of contrast but not perfusion, 2A: some perfusion <50% of vascular territory, 2B: substantial perfusion ≥50%, 3: complete perfusion of vascular territory. cClinical deterioration due to
intracranial hemorrhage defined by the Heidelberg bleeding classification.
FIGURE 3 | Distribution of the modified Rankin Scale (mRS) score at 90 days. Functional outcomes were statically significant different between patients with carotid
artery dissection and with atherosclerotic carotid artery occlusion but also compared to patients without carotid artery dissection or atherosclerotic occlusion (resp.
cOR 2.05; 95%CI 1.17–3.57 and cOR 1.60; 95%CI 1.07–2.38). After adjustments for sex, age, stroke severity (NIHSS) at baseline, time from stroke onset to
intervention hospital, intravenous thrombolysis, collateral status and location of intracranial occlusion, functional outcome was no longer statistically different (resp.
acOR 1.72; 95%CI 0.84–3.50 and acOR 1.00; 95%CI 0.64–1.56).
or ACAO. Impact of reperfusion grade on functional outcome
was comparable between patients with CAD and patients without
COD (Table 3).
Determinants of Functional Outcome in
Patients With CAD
Age (cOR 0.95 [95%CI 0.92–0.99]), baseline NIHSS (cOR 0.90
[95%CI 0.83–0.98]) and collateral status on CTA (cOR 2.20
[95%CI 1.13–4.29]) were significantly associated with a good
functional outcome in patients with CAD. (Table 3). However,
in multivariable analysis, only collateral status on CTA remained
independently associated with good functional outcome (acOR
2.11 [95%CI 1.02–4.36]) (Table 3).
DISCUSSION
In this observational study, neurological improvement after EVT
in patients with CAD was significantly larger than in patients
with a tandem occlusion due to ACAO, while rates of successful
reperfusion were similar. Short term neurological improvement
after EVT between patients with CAD and those without CAD or
ACAO was of similar magnitude. However, at 3 months follow-
up, patients with CAD were significantly more often functionally
independent compared than patients without CAD or ACAO.
This can be explained by the fact that patients with CAD were
younger and had less cardiovascular risk factors. These findings
are consistent with a recent systematic review that showed that a
large proportion of patients with tandem occlusion due to CAD
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achieved functional independency after EVT (18). Furthermore,
we observed longer procedural times and lower rates of successful
reperfusion in patients with CAD and ACAO. This might
reflect the technical challenge of passing the extracranial carotid
artery obstruction.
Regarding safety aspects, no differences were found between
EVT-treated patients with CAD or without CAD/ACAO.
Although passing the intimal tear in a CAD carries the risk
of dislodging new emboli, embolization of thrombus to a new
vascular territory did not occur more often in the CAD group.
Furthermore, the rate of symptomatic ICH was not higher
in patients with CAD, despite our finding that CAD patients
suffered from larger occlusions (more distal ICA and ICA-
T occlusions) and had a lower ASPECTS score at baseline.
Our finding that the rate of complications in EVT-treated
patients with CAD is not increased, corresponds with previous
research (18, 19).
In a recent observational study, patients with CAD were
compared to patients with severe stenosis (>90%) or occlusion
due to atherosclerotic disease (7). Procedural times were
comparable, however, rates of successful reperfusion were
lower in our study compared to other cohort studies on
endovascular treatment in clinical practice (20, 21). This finding
might be explained by our core laboratory assessment which
reduces overestimation due to operator bias (22, 23). Also,
multiple retrospective studies on EVT-treated patients with
CAD, showed comparable results regarding outcomes and safety
aspects (19, 24, 25).
TABLE 3 | Univariable and multivariable analysis of functional outcome in
EVT-treated patients with CAD.
Univariable Multivariable
cOR 95%CI acOR 95%CI
Sex (male) 0.51 0.20 –1.30 0.49 0.18 –1.36
Age 0.95 0.92 –0.99 0.98 0.93 –1.02
Stroke severity (NIHSS) at baseline 0.90 0.82 –0.98 0.91 0.83 –1.01
Time from stroke onset to groin puncture 1.00 0.99 –1.01 1.00 0.99 –1.01
Intravenous thrombolysis 2.38 0.74 –7.67 3.39 0.94 –12.19
Collateral status 2.17 1.20 –3.90 2.11 1.02 –4.36
Location of intracranial occlusion 1.09 0.66 –1.79 0.81 0.47 –1.39
cOR, common odds ratio; acOR, adjusted common odds ratio; 95%CI, 95% confidence
interval.
Several limitations of our study need to be addressed. Firstly,
we could not evaluate the effectiveness of EVT due to the absence
of an untreated control group in our observational study. A
pooled analysis of patient-level data of larger EVT trails would be
possible, however, only two trials (MR CLEAN and REVASCAT)
allowed for inclusion of patients with CAD (10, 26). Performing a
randomized controlled trial would be best to determine whether
EVT is effective compared to no EVT. This may not be feasible
in light of the low number of patients with an intracranial
occlusion in combination with a CAD. Furthermore, despite
extracranial tandem lesions, intracranial occlusions are nowadays
routinely treated in daily practice based on previous results (5,
27). Our results confirm that this is a reasonable policy. Secondly,
we performed an observational multicenter study. Selection of
patients and treatment strategy may vary between intervention
centers, introducing selection bias. We tried to minimize this
bias by adjusting for prognostic factors in multivariable analyses,
and by comparing different groups of patients. Thirdly, due
to the retrospective design of our study, we were not able to
perform additional analyses on the technical management of
tandem lesions. This data would be of interest as there is an
ongoing debate whether a diseased ICA should be treated or left
alone during EVT. In addition, recent literature, suggests that
the treatment of the intracranial occlusion should have priority
over possible treatment of the affected ICA (28–31). Fourthly,
the long-term follow-up was no longer than 3 months in the
MR CLEAN Registry. Therefore, we were not able to assess the
occurrence of recurrent strokes over a longer time period.
We observed that EVT in patients with ipsilateral CAD are
technically more challenging due to the additional obstruction of
extracranial carotid artery. However, neurological improvement
at short term is not different from patients without CAD or
ACAO and suggests a comparable treatment effect. At follow-up,
the chances of gaining functional independence are even larger in
patients with CAD compared to patients without CAD or ACAO,
likely because patients with CAD are younger, healthier, and are
burdened less with atherosclerotic and cardiac disease.
In summary, EVT in patients with intracranial LVO due to
CAD results in neurological improvement comparable to patients
without tandem occlusion. Therefore, carotid artery dissection by
itself should not be a contraindication for endovascular treatment
in stroke patients with intracranial large vessel occlusion.
Although more challenging endovascular procedures are to
be suspected in both patients with CAD or ACAO, accurate
TABLE 4 | Proportions of functional independence stratified by reperfusion grades.
Patients with CAD
(n = 74)
Patient with ACAO
(n = 92)
Patients without CAD or ACAO
(n = 1,398)
mTICI-score* N (%) mRS 0–2 (%) N (%) mRS 0–2 (%) N (%) mRS 0–2 (%)
0–1 15 4 (19) 20 2 (10) 266 41 (15)
2a 19 11(58) 22 7 (32) 272 81 (30)
2b−3 32 19 (59) 47 15 (32) 729 348 (48)
cOR (95%CI) 1.35 (1.02–1.78) 1.34(1.18–1.66) 1.36(1.28–1.44)
*Score of 0 indicates no perfusion or anterograde flow beyond occlusion site, 1: penetration of contrast but not perfusion, 2A: some perfusion <50% of vascular territory, 2B: substantial
perfusion ≥50, 3: complete perfusion of vascular territory.
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distinction between CAD and ACAO might influence clinical
decision making as better clinical outcome can be expected in
patients with CAD.
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